AYTU:NSD-Aytu Biopharma Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 1.19

Change

+0.01 (+0.85)%

Market Cap

USD 0.03B

Volume

0.13M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Aytu Biopharma Inc (AYTU) Stock Analysis:
Based on the Aytu Biopharma Inc stock forecasts from 0 analysts, the average analyst target price for Aytu Biopharma Inc is not available over the next 12 months. Aytu Biopharma Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Aytu Biopharma Inc is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, Aytu Biopharma Inc’s stock price was USD 1.19. Aytu Biopharma Inc’s stock price has changed by -0.09% over the past week, -0.33% over the past month and -85.75% over the last year.

About

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity di ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-25 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
NBIX Neurocrine Biosciences Inc

+0.07 (+0.09%)

USD7.20B 16.70 37.25
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
ITCI Intra-Cellular Therapies Inc

+2.30 (+5.19%)

USD3.92B N/A N/A
PCRX Pacira BioSciences Inc

-1.45 (-2.29%)

USD2.82B 46.64 19.70
TLRY Tilray Inc

-0.12 (-2.05%)

USD2.70B N/A N/A
CGC Canopy Growth Corporation

-0.04 (-0.54%)

USD2.66B N/A N/A
IRWD Ironwood Pharmaceuticals Inc

-0.06 (-0.54%)

USD1.80B 3.39 7.38
SUPN Supernus Pharmaceuticals Inc

+0.56 (+1.92%)

USD1.55B 19.32 9.45

ETFs Containing AYTU

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.85% 58% F 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.85% 58% F 42% F
Trailing 12 Months  
Capital Gain -85.75% 14% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -85.75% 14% F 4% F
Trailing 5 Years  
Capital Gain -99.64% 3% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.64% 3% F 1% F
Average Annual (5 Year Horizon)  
Capital Gain -44.68% 2% F N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -44.68% 2% F N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 46.56% 52% F 37% F
Risk Adjusted Return -95.96% 8% F 1% F
Market Capitalization 0.03B 12% F 10% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.10 88% B+ 94% A
Price/Book Ratio 0.43 98% A+ 98% A+
Price / Cash Flow Ratio -1.28 36% F 57% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -80.80% 33% F 14% F
Return on Invested Capital -28.51% 47% F 24% F
Return on Assets -14.54% 54% F 25% F
Debt to Equity Ratio 0.13% 77% C+ 90% A-
Technical Ratios  
Short Ratio 1.98 68% D+ 56% F
Short Percent 5.76% 49% F 28% F
Beta -0.37 99% A+ 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector